Optimizerx Corporation (OPRX)
NASDAQ (CM) NASDAQ (CM) Primary 
Should You Add OPRX Stock to Your Portfolio Pre-Q1 Earnings?
OptimizeRx nears Q1 earnings amid declining revenue forecasts, softer trends and a cautious outlook, raising questions on near-term upside.
Earnings Preview: OptimizeRx Corp. (OPRX) Q1 Earnings Expected to Decline
OptimizeRx (OPRX) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Are Investors Undervaluing OptimizeRx (OPRX) Right Now?
Here at Zacks, our focus is on the proven Zacks Rank system, which emphasizes earnings estimates and estimate revisions to find great stocks. Nevertheless, we are always paying attention to the latest value, growth, and momentum trends to underscore strong picks.
OptimizeRx vs. GoodRx: Which Digital Health Stock is the Better Buy?
OPRX edges past GDRX with AI-driven platform momentum, stronger estimates and lower valuation despite near-term revenue headwinds.
Can OptimizeRx's Cash Strength Cushion Near-Term Headwinds?
OPRX's rising cash flow, DAAP adoption and expanding pharma ties boost outlook despite near-term revenue softness and cautious client spending.
OPRX Trades at a Discount to Industry: How to Approach the Stock Now?
OptimizeRx trades at a steep discount to peers, but strong AI-driven growth, rising cash flow and DAAP traction look encouraging.
Should Value Investors Buy OptimizeRx (OPRX) Stock?
Here at Zacks, our focus is on the proven Zacks Rank system, which emphasizes earnings estimates and estimate revisions to find great stocks. Nevertheless, we are always paying attention to the latest value, growth, and momentum trends to underscore strong picks.
OPRX Cuts Revenue Outlook: Temporary Reset or Structural Concern?
OptimizeRx lowers 2026 revenue forecast on shifting pharma spend and managed services drag, but signals recovery ahead and stronger EBITDA expectations.
Are Investors Undervaluing OptimizeRx (OPRX) Right Now?
Here at Zacks, our focus is on the proven Zacks Rank system, which emphasizes earnings estimates and estimate revisions to find great stocks. Nevertheless, we are always paying attention to the latest value, growth, and momentum trends to underscore strong picks.
OptimizeRx (OPRX) Soars 5.9%: Is Further Upside Left in the Stock?
OptimizeRx (OPRX) saw its shares surge in the last session with trading volume being higher than average. The latest trend in earnings estimate revisions may not translate into further price increase in the near term.
OptimizeRx Corporation (OPRX) Q4 2025 Earnings Call Transcript
OptimizeRx Corporation (OPRX) Q4 2025 Earnings Call Transcript
OptimizeRx Corp. (OPRX) Q4 Earnings and Revenues Beat Estimates
OptimizeRx Corp. (OPRX) came out with quarterly earnings of $0.51 per share, beating the Zacks Consensus Estimate of $0.23 per share. This compares to earnings of $0.3 per share a year ago.
